Recent investigations on retatrutides, a dual activator for incretin hormone and glucose-dependent insulinotropic polypeptide, suggest promising results in managing obesity and type 2 glucose intolerance. Early evidence from clinical experiments reveal considerable reductions in body bulk and bettered glucose control. Further research is directed o